3-ethyl-4-methoxyphenol | 13523-64-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-ethyl-4-methoxyphenol
• 英文别名: 3-Ethyl-4-methoxy-phenol
• CAS: 13523-64-3
• 化学式: C₉H₁₂O₂
• 分子量: 152.193
• InChiKey: YBHFXIXJNDNBQG-UHFFFAOYSA-N

物化性质

• 沸点：
  75 °C(Press: 0.12 Torr)
• 密度：
  1.051±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-ethyl-4-methoxyphenol 在 palladium on activated charcoal 氢气 、 三溴化硼 、 sodium hydride 作用下， 以 乙醇 为溶剂， 生成 4-(4-Amino-2,6-dimethylphenoxy)-2-ethylphenol
  参考文献：
  名称：

  Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to l-thyronine

  摘要：

  The synthesis of substituted phenoxyphenyl oxamic acid derivatives related to L-thyronine (L-T-3) is described. The in vitro and in vivo cholesterol lowering and cardiovascular effects of these compounds are presented and discussed. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00309-7
• 作为产物：
  描述：

  1,4-二羟基-2-乙基苯 在 盐酸 、 potassium carbonate 作用下， 生成 3-ethyl-4-methoxyphenol
  参考文献：
  名称：

  Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to l-thyronine

  摘要：

  The synthesis of substituted phenoxyphenyl oxamic acid derivatives related to L-thyronine (L-T-3) is described. The in vitro and in vivo cholesterol lowering and cardiovascular effects of these compounds are presented and discussed. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00309-7

文献信息

• FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
  申请人：Kusakabe Ken-ichi

  公开号：US20120059162A1

  公开（公告）日：2012-03-08

  Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.

  提供了一个由一般式（1）表示的化合物，具有TTK抑制作用，以及含有该化合物的药物。在式（1）中，（X，Y，V，W）为（—N═，═CR1—，═N—，—CR7═），（—CR2═，═N—，═N—，—CR7═），等等；A为（非）取代芳香烃环等；L为一个单键，—C(═O)—NRA—等；Z为由式—NR3R4或式—OR5表示的基团；R1至R3，R6和R7分别是氢原子等；R4和R5分别是（非）取代烷基等；R8是（非）取代环烷基等。
• 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
  申请人：Lophora ApS

  公开号：US20210137908A1

  公开（公告）日：2021-05-13

  The present invention relates to agonists of the 5-HT 2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT 2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT 2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT 2A /5-HT 2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT 2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT 2A agonist for the use in the treatment of treatment-resistant depression.

  本发明涉及5-HT2A 5-羟色胺受体的激动剂及其医疗用途。在一个方面，本发明涉及式(I)的5-HT2A激动剂。在第二个方面，本发明涉及式(II)的选择性5-HT2A激动剂。在另一个方面，本发明涉及式(III)的混合5-HT2A/5-HT2C激动剂。在另一个方面，本发明涉及用于治疗抑郁症的5-HT2A激动剂，更具体地说是用于治疗难治性抑郁症的5-HT2A激动剂。
• Re₂O₇catalyzed dienone-phenol rearrangement
  作者：Zilei Xia、Jiadong Hu、Zhigao Shen、Qizheng Yao、Weiqing Xie

  DOI：10.1039/c5ra04931h

  日期：——

  The dienone-phenol rearrangement of 4,4-disubstituted cyclohexadienones catalyzed by Re2O7 has been described. Multi-substituted phenols can be efficiently obtained in good to excellent yields by employing this catalytic protocol.

  已经描述了由Re 2 O 7催化的4，4-二取代的环己二酮的二烯酮-苯酚重排。通过使用该催化方案，可以以良好或优异的收率有效地获得多取代的苯酚。
• Piperidine derivatives having ccr3 antagonism
  申请人：Matsumoto Yoshiyuki

  公开号：US20070032525A1

  公开（公告）日：2007-02-08

  The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C 1 -C 6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

  本发明提供了具有抑制CCR3配体结合到靶细胞CCR3的活性的低分子化合物，即CCR3拮抗剂。本发明还提供了由下式（I）表示的化合物，其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的制药组合物，用于治疗或预防与CCR3相关的疾病，例如哮喘和过敏性鼻炎。
• HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES
  申请人：Olesen Preben Houlberg

  公开号：US20100041657A1

  公开（公告）日：2010-02-18

  The present invention relates to compounds of formula I, in which at least one of R5, R6 and R7 is SR12, S(O)R12 or S(O)2R12 group where R12 is a C1-6haloalkyl group, that act, as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.

  本发明涉及公式I的化合物，其中R5，R6和R7中至少有一个是SR12，S（O）R12或S（O）2R12基团，其中R12是C1-6卤代烷基基团，可作为化学解偶联剂。本发明的化合物在治疗，包括预防肥胖症，糖尿病以及与之相关的许多疾病或病况方面非常有用。